阿托伐他汀钙对高血压病患者血清高敏C反应蛋白及B型利钠肽的影响

Effect of atorvastatin calcium on High-sensitivity C-reactive Protein and N-terminal proBNP in Esstential Hypertensive Patients

目的探讨阿托伐他汀对高血压病患者高敏C反应蛋白(hs-CRP)、B型利钠肽浓度的影响。方法选择88例高血压病患者,经2周安慰剂治疗后随机分为2组,治疗组给予阿托伐他汀钙,每晚20mg,硝苯地平控释片30mg,每日1次,对照组给予硝苯地平控释片30 mg,1次/d。疗程为8周。在2周洗脱期末及8周末空腹抽静脉血,测定hs–CRP、N末端脑钠肽水平。比较治疗前后hs–CRP、N末端脑钠肽前体浓度变化。结果两组患者治疗前后收缩压、舒张压均有显著下降,差异有统计学意义(P<0.01);阿托伐他汀组治疗后血清hs-CRP、N末端脑钠肽前体与治疗前比较差异有统计学意义(P<0.01),对照组治疗后hs-CRP与治疗前比较差异无统计学意义(P>0.05)。治疗组治疗前后hs-CRP、N末端脑钠肽前体差值与对照组比较差异有统计学意义(P<0.01,P<0.05)。结论阿托伐他汀钙可有效降低高血压患者hs-CRP及N末端脑钠肽前体水平。

Objective To investigate the effect of atorvastatin calcium on serum high-sensitivity C-reactive protein( hs-CRP)and N-terminal proBNP(NT-proBNP) in hypertensive patients. Methods After two weeks of single blind placebo period,88 hypertensive patients were divided into experimental group(atorvastatin calcium 20 mg, once per night,nifedipine controlled-release tablets 30 mg,once per day) and control group(nifedipine controlled-release tablets 30 mg,once per day)for eight weeks for both groups. The level of NT-proBNP and hs-CRP were evaluated before and the end of treatment. Results SBP and DBP were significantly reduced in two groups after treatment(P < 0.01). In experimental group,the level of hs-CRP, NT-proBNP were significantly decreased after treatment(P <0.01).In control group,the level of hs-CRP were no significant differences after treatment(P>0.05). Conclusion Atorvastatin calcium can Further reduce hs-CRP and NT-proBNP in hypertensive patients.